Progestogen-only contraception: A review

Practitioner

Volumn 249, Issue 1667, 2005, Pages 90-102

  Gupta, Sunanda ^a,b  

^a Waltham Forest Primary Care Trust ^*  (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ETYNODIOL DIACETATE; LEVONORGESTREL; NORETHISTERONE; PROGESTERONE;

CONFERENCE PAPER; CONTRACEPTION; HEALTH CARE; HUMAN; IMPLANT; INFLAMMATION; OSTEOPOROSIS; PREGNANCY; PREGNANCY RATE; RISK FACTOR; UNITED KINGDOM; VAGINA RING;

CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; DRUG IMPLANTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEVONORGESTREL; PROGESTINS;

EID: 13644270558     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Dawes F, Meltzer H. Contraception and sexual health 2001. London:ONS 2003
2. Vessey M, Painter R. Oral contraceptive failures and bodyweight: Findings in a large cohort study. J Fam Plan Reprod Health Care 2001;27(2):90-1
3. CEU - member's enquiry service. J Fam Plan Reprod Healthcare 2003;29(3):1
4. Rice CF, Killick SR, Dieben TOM et al. A comparison of the inhibition of ovulation achieved by desogestrel 75mg and levonorgestrel 30mg daily. Human Repro 1999;14:982-5
5. WHO. Improving access to quality care in family planning, medical eligibility criteria for contraceptive use. Geneva: WHO, 2004
6. Gallo MF, Grimes DA, Schulz KF et al. Combination contraceptives: effect on weight. The Cochrane library Issue 4, 2003
7. WHO selected practice recommendations for contraceptive use 2002. Geneva: WHO, 2002. ISBN 92. 154566 6
8. Wilcox AJ, Dunson DB, Weinberg CR et al. Likelihood of conception - a single act of intercourse: providing benchmark rates for assessment of post coital contraceptives. Contraception 2001;63:211-5
9. Llang AP, Levenson AG, Layde P Metal. Risk of breast, uterine, corpus and ovarian cancer in women receiving MPA injections. JAMA 1983;249:2909-12
10. Skegg DC, Noonan EA, Paul C et al. DMPA and breast cancer: A pooled analyses of the WHO and New Zealand studies. JAMA 1995;273:799-804
11. Connor PD et al. Determining risk both Depo-Provera use and increased uterine bleeding in obese and overweight women. J Am Board Fam Prac 2002;15:7-10
12. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using DMPA. J Paediatr Adol Gyn 2002;15:79-82
13. Westhoff C. Depressive symptoms and Depo-Provera. Contraception 1998;57:237-40
14. Lara-Torre E et al. J Paediatr Adol Gyn 2004;17:17-21
15. Cundy T et al. Menopausal bone loss - long term users of DMPA. Am J Obstet & Gynecol 2002;186:978-83
16. Clark MK, Sowers MFR, Sara Nichols et al. Bone mineral density changes over 2 years - first time users of DMPA. Fertil Steril 2004;82(6):1580-86
17. Smith JS et al. cervical cancer and use of hormonal contraceptives, a systematic review. Lancet 2003;361:1159-67
18. Beerthuizen R, Van Beek A, Massau R et al. Bone mineral density during long term use of the progestogen contraceptive implant Implanon compared to a non hormonal method of contraception. Hum Repr 2000;15:118-22
19. Anderson K, Odland V, Rybo G. Levonorgestrel releasing and Cu-releasing Nova T IUDs during five years of use, a randomised comparative trial. Contraception 1994;49:56-72
20. Teisala K. Removal of an IUD and treatment of pelvic inflammatory disease. Ann Med 1989;21:63-5
21. Bound W, Guillebaud J. Observational studies on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme inducing drugs. J Fam Plan Repr Health Care 2002;28:78-80
22. Hurskounen MD, Rissanen P, Grenman S, Kujansuu E. Clinical outcome and costs with the levonorgestrel intrauterine system or hysterectomy for treatment of menorrhagia. A randomised trial 5 year follow-up. JAMA 2004;291(12):1456-63
23. Fedele L, Portuese A, Bianchi S et al. Treatment of adenonyoss associated menorrhagia with a levonorgestrel releasing IUD. Fertil Steril 1997;68:426-9
24. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 mcg and Cu T 380 Ag IUD: a multicentre study. International Committee for Contraceptive Research. Fertil Steril 1994;61:70-7
25. Fedele L, Bianchiu S, Zienconato G et al. Use of levonorgestrel releasing IUD in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75:485-8
26. Gugorieva V, Chen Moh M, Tarasova Mental. Use of a levonorgestrel releasing IUS to treat bleeding related to uterine leiromyomas. Fertil Steril 2003;79:1194-8
27. Raudoskoski T, Tapanainen J, Thomas et al. Intrauterine 10mg and 20mg LNG systems in postmenopausal women oral estradiol replacement therapy. Br J Obstetr Gynaecol 2002;109:36-44
28. Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with the levonorgestrel intra-uterine system. Am J Obstet Gynecol 2003;188:1297-8
29. Farley T, Rosenberg M, Rowe P et al. IUDs and pelvic inflammatory disease, an international perspective. Lancet 1992;339:785-8